Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Levodopa-Induced Neuropathy: A Systematic Review.

Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L.

Mov Disord Clin Pract. 2018 Nov 8;6(2):96-103. doi: 10.1002/mdc3.12688. eCollection 2019 Feb. Review.

PMID:
30838307
2.

Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management.

Uncini A, Eleopra R, Onofrj M.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):490-5. doi: 10.1136/jnnp-2014-308586. Epub 2014 Aug 28. Review.

PMID:
25168395
3.

Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.

Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L.

Eur J Neurol. 2016 Mar;23(3):501-9. doi: 10.1111/ene.12846. Epub 2015 Oct 25.

PMID:
26498913
4.

Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.

Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A.

Parkinsonism Relat Disord. 2013 May;19(5):501-7 ; discussion 501. doi: 10.1016/j.parkreldis.2013.02.006. Epub 2013 Feb 27. Review.

5.

Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.

Andréasson M, Brodin L, Laffita-Mesa JM, Svenningsson P.

J Parkinsons Dis. 2017;7(4):619-628. doi: 10.3233/JPD-171127.

PMID:
28759974
6.

Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.

Rispoli V, Simioni V, Capone JG, Golfrè Andreasi N, Preda F, Sette E, Tugnoli V, Sensi M.

Acta Neurol Scand. 2017 Dec;136(6):660-667. doi: 10.1111/ane.12783. Epub 2017 Jun 12.

PMID:
28608472
7.

Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.

Wirdefeldt K, Odin P, Nyholm D.

CNS Drugs. 2016 May;30(5):381-404. doi: 10.1007/s40263-016-0336-5. Review.

PMID:
27138916
8.

Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.

Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS.

J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.

PMID:
26777085
9.

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.

Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C.

Brain Behav. 2017 Apr 7;7(5):e00698. doi: 10.1002/brb3.698. eCollection 2017 May.

10.
11.

Polyneuropathy in levodopa-treated Parkinson's patients.

Szadejko K, Dziewiatowski K, Szabat K, Robowski P, Schinwelski M, Sitek E, Sławek J.

J Neurol Sci. 2016 Dec 15;371:36-41. doi: 10.1016/j.jns.2016.09.061. Epub 2016 Oct 2.

PMID:
27871444
12.

Malnutritional neuropathy under intestinal levodopa infusion.

Klostermann F, Jugel C, Müller T, Marzinzik F.

J Neural Transm (Vienna). 2012 Mar;119(3):369-72. doi: 10.1007/s00702-011-0689-3. Epub 2011 Jul 24.

PMID:
21786115
13.

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Wang L, Li J, Chen J.

Front Neurol. 2018 Jul 30;9:620. doi: 10.3389/fneur.2018.00620. eCollection 2018.

14.

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.

Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.

15.

Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.

Othman AA, Chatamra K, Mohamed ME, Dutta S, Benesh J, Yanagawa M, Nagai M.

Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.

16.

Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.

Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti Moja M, Riboldazzi G, Tunesi S, Dal Fante M, Manfredi L, Lacerenza M, Cantello R, Antonini A.

Parkinsonism Relat Disord. 2014 Jan;20(1):27-31. doi: 10.1016/j.parkreldis.2013.09.007. Epub 2013 Sep 25.

PMID:
24099722
17.
18.

Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?

Devigili G, Rinaldo S, Lettieri C, Eleopra R.

Muscle Nerve. 2016 Nov;54(5):970-972. doi: 10.1002/mus.25377. Epub 2016 Sep 26.

PMID:
27514937
19.

Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.

Matsuyama H, Matsuura K, Ishikawa H, Hirata Y, Kato N, Niwa A, Narita Y, Tomimoto H.

Brain Behav. 2018 Dec;8(12):e01143. doi: 10.1002/brb3.1143. Epub 2018 Oct 25.

20.

Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.

Pålhagen SE, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, Dizdar N, Linder J, Hauge T, Jansson R, Bergmann L, Kjellander S, Marshall TS.

Parkinsonism Relat Disord. 2016 Aug;29:17-23. doi: 10.1016/j.parkreldis.2016.06.002. Epub 2016 Jun 4.

Supplemental Content

Support Center